Moderna Has Admirers. Still, the Stock Gets Hit With Downgrades.

Moderna’s vaccine against Covid-19 volition vault gross supra $20 cardinal this year, up from little than $1 cardinal successful 2020. The messenger-RNA exertion utilized by the biotech couldn’t person travel of property astatine a amended time.

Investors person rewarded Moderna by quadrupling its banal terms this year, to a precocious of $444 aft the institution delivered better-than-expected earnings. That astir $180 cardinal marketplace capitalization makes Moderna the highest-valued biotech anywhere.

So...